Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 3 countries.
Enrique-J MontagutNanobiotechnology for Diagnostics (Nb4D), Department of Surfactants and Nanobiotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), 08750 Barcelona, Spain.
Gerardo AcostaCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid Spain.
Fernando AlbericioCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid Spain.
Miriam RoyoCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28029 Madrid Spain.ORCID 0000-0001-5292-0819
Gerard Godoy-TenaServei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.
Alicia LacomaServei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID 0000-0002-2049-3872
Cristina PratServei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID 0000-0001-6974-9165
Juan-Pablo SalvadorNanobiotechnology for Diagnostics (Nb4D), Department of Surfactants and Nanobiotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), 08750 Barcelona, Spain.
María-Pilar MarcoNanobiotechnology for Diagnostics (Nb4D), Department of Surfactants and Nanobiotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), 08750 Barcelona, Spain.ORCID 0000-0002-4064-1668
Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESUniversitat Autònoma de Barcelona · ES
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
An immunochemical strategy to detect and quantify AIP-IV, the quorum sensing (QS) signaling molecule produced by
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Direct Quantitative Immunochemical Analysis of Autoinducer Peptide IV for Diagnosing and Stratifying · full record | OpenQuestion